Gentian Diagnostics: First quarter 2025 report

07 May 2025 08:00 CEST

Moss, 7 May 2025

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the first quarter 2025.

Highlights include:

Record sales of NOK 44.5 million in 1Q25, up 16% vs 1Q24 (13% organic growth).

Sales of Cystatin C increased with 18% in 1Q25 compared to 1Q24. Strong increase
in sales to China
indicates a return towards a normalised supply situation.

Continued US sales growth of 31% in 1Q25 with several new Cystatin C customers
onboarded.

Improvement of gross margin to 64%, up from 53% in 1Q24, mainly driven by strong
operational performance.

Significant EBITDA improvement to NOK 14.0 million in 1Q25 versus NOK 4.8
million in 1Q24.

Net profit of NOK 7.8 million versus NOK 4.2 million in 1Q24.

Beckman Coulter launched GCAL securing increased market access.

Patent application in Japan accepted protecting Gentian’s innovative approach to
NT-proBNP measurement
using turbidimetric immunoassay technology.


Webcast

The company will present the results today at 10.00 am, followed by a Q&A
session. The presentation will be held as a live webcast on the company's
website:

https://www.gentian.com/investor-relation/presentations

The webcast will also be available on the company website after the
presentation.


IR contact:

Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)


This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 7 May 2025 at 08:00 CEST.


About Gentian
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian’s expertise and focus lies within
immunoassays, specifically for infections, inflammation, kidney failure and
congestive heart failure. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian Diagnostics is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

More information:
Access the news on Oslo Bors NewsWeb site

645506_GDASA Interim report 1Q 2025.pdf
645506_GDASA Q1 25 presentation.pdf